PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells

International Journal of Molecular Medicine

Volumn 20, Issue 1, 2007, Pages 11-20

  Jankun, Jerzy ^a,b   Aleem, Ansari M ^a   Specht, Zofia ^a,b   Keck, Rick W ^a   Lysiak Szydlowska, Wieslawa ^b   Selman, Steven H ^a   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cancer; Cell detachment; Fortilin; Nucleophosmin; Plasminogen activator inhibitor

Indexed keywords

NUCLEAR PROTEIN; NUCLEOPHOSMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN, P23; TUMOR MARKER; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; GENETICS; HALF LIFE TIME; HUMAN; MALE; METABOLISM; MOLECULAR WEIGHT; PROSTATE TUMOR; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HALF-LIFE; HUMANS; MALE; MODELS, MOLECULAR; MOLECULAR WEIGHT; NUCLEAR PROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548089505     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.1.11     Document Type: Article

References (44)

1. Lah TT, Duran Alonso MB and van Noorden CJ: Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 6: 257-279, 2006.
2. Ludwig T: Local proteolytic activity in tumor cell invasion and metastasis. Bioessays 27: 1181-1191, 2005.
3. Schirrmacher V: Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res 43: 1-73, 1985.
4. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.
5. Vihinen P, Ala-aho R and Kahari VM: Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5: 203-220, 2005.
6. Arlen PM, Gulley JL, Parker C, et al: A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12: 1260-1269, 2006.
7. Lara PN Jr, Stadler WM, Longmate J, et al: A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12: 1556-1563, 2006.
8. Molina JR, Reid JM, Erlichman C, et al: A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs 16: 997-1002, 2005.
9. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2: 19-28, 2003.
10. Jedinak A and Maliar T: Inhibitors of proteases as anticancer drugs. Neoplasma 52: 185-192, 2005.
11. Puli S, Lai JC and Bhushan A: Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones. J Neurooncol 79: 135-142, 2006.
12. Menashi S, Lu H, Soria C and Legrand Y: Endothelial cell proteases: physiological role and regulation. Baillieres Clin Haematol 6: 559-576, 1993.
13. Inoue M, Sawada T, Uchima Y, et al: Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep 14: 1445-1451, 2005.
14. Van Hinsbergh VW, Engelse MA and Quax PH: Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26: 716-728, 2006.
15. Lawrence DA, Strandberg L, Ericson J and Ny T: Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. J Biol Chem 265: 20293-20301, 1990.
16. Tucker HM, Mottonen J, Goldsmith EJ and Gerard RD: Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol 2: 442-445, 1995.
17. Usher PA, Thomsen OF, Iversen P, et al: Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer 113: 870-880, 2005.
18. Andreasen PA, Egelund R and Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57: 25-40, 2000.
19. Dellas C and Loskutoff DJ: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93: 631-640, 2005.
20. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT and Pannekoek H: Alteration of serpin specificity by a protein co-factor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265: 13029-13035, 1990.
21. Lambers JW, Cammenga M, Konig BW, Mertens K, Pannekoek H and van Mourik JA: Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 262: 17492-17496, 1987.
22. Bergstralh DT, Conti BJ, Moore CB, Brickey WJ, Taxman DJ and Ting JP: Global functional analysis of nucleophosmin in Taxol response, cancer, chromatin regulation, and ribosomal DNA transcription. Exp Cell Res 313: 65-76, 2007.
23. Bommer UA and Thiele BJ: The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 36: 379-385, 2004.
24. De Lano WL: The PyMOL molecular graphics system. PyMOL v. 0.98., 2005.
25. Guex N and Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723, 1997.
26. Cohen GE: ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J Appl Crystallograph 30: 1160-1161, 1997.
27. Amagata T, Whitman S, Johnson TA, et al: Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod 66: 230-235, 2003.
28. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
29. Basrur V, Yang F, Kushimoto T, et al: Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res 2: 69-79, 2003.
30. Jankun J, Maher VM and McCormick JJ: Malignant transformation of human fibroblasts correlates with increased activity of receptor-bound plasminogen activator. Cancer Res 51: 1221-1226, 1991.
31. Seiffert D and Loskutoff DJ: Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. Biochim Biophys Acta 1078: 23-30, 1991.
32. Lawrence DA, Olson ST, Palaniappan S and Ginsburg D: Engineering plasminogen activator inhibitor 1 mutants with increased functional stability. Biochemistry 33: 3643-3648, 1994.
33. Jankun J, Specht Z, Szkudlarek M, et al: Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. Int J Mol Med 17: 437-447, 2006.
34. Lee HJ and Im H: Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies. Protein Expr Purif 31: 99-107, 2003.
35. Hagglof P, Bergstrom F, Wilczynska M, Johansson LB and Ny T: The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol 335: 823-832, 2004.
36. Balsara RD, Castellino FJ and Ploplis VA: A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 281: 22527-22536, 2006.
37. Czekay RP, Aertgeerts K, Curriden SA and Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 160: 781-791, 2003.
38. Boncela J, Papiewska I, Fijalkowska I, Walkowiak B and Cierniewski CS: Acute phase protein alpha 1-acid glycoprotein interacts with plasminogen activator inhibitor type 1 and stabilizes its inhibitory activity. J Biol Chem 276: 35305-35311, 2001.
39. Grisendi S, Mecucci C, Falini B and Pandolfi PP: Nucleophosmin and cancer. Nat Rev Cancer 6: 493-505, 2006.
40. Slupianek A, Nieborowska-Skorska M, Hoser G, et al: Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61: 2194-2199, 2001.
41. Ii M, Yamamoto H, Adachi Y, Maruyama Y and Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 231: 20-27, 2006.
42. Tuynder M, Fiucci G, Prieur S, et al: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 101: 15364-15369, 2004.
43. Tuynder M, Susini L, Prieur S, et al: Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA 99: 14976-14981, 2002.
44. Zhang G, Cai X, Lopez-Guisa JM, Collins SJ and Eddy AA: Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. J Am Soc Nephrol 15: 2090-2102, 2004.